{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:19:43Z","timestamp":1783491583313,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Radioiodine therapy (RIT) is a well established adjuvant therapy in intermediate and high-risk patients of well differentiated thyroid cancer (WDTC). Diagnostic whole-body radioiodine (WBRI) scans are done to evaluate remnant lesions and metastatic burden. Sometimes, diffuse liver uptake is noted in WBRI scans, even in the absence of liver metastasis. Few studies have assessed the hepatic\u2013thigh ratio (HTR) on WBRI and found its correlation with the functional status of tumour cells and prognostication. We assessed the baseline HTR in WDTC and evaluated the dynamics of HTR in different groups after RIT in the follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty WDTC patients (30 in metastatic and 30 in nonmetastatic groups) were included in a prospective study. Patients underwent baseline WBRI scans, and RIT was done. Follow-up was conducted at six and 12 months, including biochemical investigations and WBRI. The baseline hepatic-to-thigh ratio (HTR0) was calculated as the average counts per pixel of a region of interest drawn in the right lobe of the liver and the mid-thigh. Correlation analysis of HTR0 and follow-up HTR (HTR1 and HTR2) with tumour markers, liver enzymes, histopathology, and outcome was done.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean ages of patients with and without metastasis were 35.8 and 42.03 years, respectively. There was no significant difference between serum thyroglobulin, serum thyroglobulin antibody (TgAb), age, thyroid-stimulating hormone, and HTR0, HTR1, and HTR2 among nonmetastasis and metastasis groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u20050.05). Papillary and follicular carcinomas were noted in 46 and 14, respectively. A complete response was noted in the 31 patients and was associated with the papillary carcinoma and HTR2\u2005&lt;\u20052.135. HTR2\u2005&lt;\u20052.135 predicted a complete response with a sensitivity and specificity of 90% and 82%, respectively. Rising HTR in follow-up was associated with incomplete response. HTR1 and HTR2 were higher in follicular carcinoma compared to papillary carcinoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HTR0 is unrelated to the disease burden (thyroglobulin and metastasis) and histopathological variant. High HTR0 is associated with poor response and residual disease. Rising HTR in follow-up also signifies the inadequate response to RIT. HTR acts as a supplementary tool to existing risk factors, and thyroglobulin for predicting therapeutic response in DTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002159","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:00:09Z","timestamp":1777287609000},"page":"951-958","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic high ratio on whole-body radioiodine scans: a robust prognostic marker in well differentiated thyroid cancer"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-5861","authenticated-orcid":false,"given":"Prakash","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, King George\u2019s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanta K","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Ora","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, King George\u2019s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita","family":"Khandelwal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"R3-20260708","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma.","volume":"361","author":"Sherman","year":"2003","journal-title":"Lancet"},{"key":"R5-20260708","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2017.04.007","article-title":"Selected controversies of radioiodine imaging and therapy in differentiated thyroid cancer.","volume":"46","author":"Van Nostrand","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R6-20260708","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/eje.1.02014","article-title":"Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report.","volume":"153","author":"Pacini","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"R7-20260708","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2967\/jnumed.121.262402","article-title":"Management of differentiated thyroid cancer: the standard of care.","volume":"63","author":"Avram","year":"2022","journal-title":"J Nucl Med"},{"key":"R8-20260708","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1210\/jc.2005-0492","article-title":"A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.","volume":"90","author":"Kloos","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20260708","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1089\/thy.2008.0160","article-title":"Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients.","volume":"18","author":"Crocetti","year":"2008","journal-title":"Thyroid"},{"key":"R10-20260708","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1210\/jc.2007-1404","article-title":"Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.","volume":"93","author":"Castagna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20260708","first-page":"1191","article-title":"Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma.","volume":"38","author":"Chung","year":"1997","journal-title":"J Nucl Med"},{"key":"R13-20260708","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s00268-001-0021-8","article-title":"Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.","volume":"25","author":"Tatar","year":"2001","journal-title":"World J Surg"},{"key":"R14-20260708","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00003072-198809000-00011","article-title":"Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma.","volume":"13","author":"Rosenbaum","year":"1988","journal-title":"Clin Nucl Med"},{"key":"R15-20260708","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/RLU.0b013e31818f433c","article-title":"Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans.","volume":"34","author":"Om\u00fcr","year":"2009","journal-title":"Clin Nucl Med"},{"key":"R16-20260708","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12149-015-0983-5","article-title":"Prediction of treatment response to 131I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer.","volume":"29","author":"Jun","year":"2015","journal-title":"Ann Nucl Med"},{"key":"R17-20260708","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13044-019-0065-1","article-title":"Semi-quantitative assessment of diffuse hepatic uptake seen in I-131 scans \u2013 an indicator of functioning thyroid tissue and disease burden in differentiated thyroid cancer.","volume":"12","author":"Pradhan","year":"2019","journal-title":"Thyroid Res"},{"key":"R18-20260708","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"R19-20260708","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1308\/rcsann.2016.0300","article-title":"Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation.","volume":"99","author":"Parameswaran","year":"2017","journal-title":"Ann R Coll Surg Engl"},{"key":"R20-20260708","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2011.0309","article-title":"Common genetic variants in sex hormone pathway genes and papillary thyroid cancer risk.","volume":"22","author":"Schonfeld","year":"2012","journal-title":"Thyroid"},{"key":"R21-20260708","first-page":"225","article-title":"Cancer statistics, 2009.","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R22-20260708","first-page":"e4127","article-title":"Epidemiology of thyroid cancer: a review of the National Cancer Database, 2000\u20132013.","volume":"11","author":"Olson","year":"2019","journal-title":"Cureus"},{"key":"R23-20260708","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/archotol.130.1.110","article-title":"Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes.","volume":"130","author":"Wang","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R24-20260708","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1055-3207(18)30404-6","article-title":"Thyroid cancer nodal metastases: biologic significance and therapeutic considerations.","volume":"5","author":"Grebe","year":"1996","journal-title":"Surg Oncol Clin N Am"},{"key":"R25-20260708","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1210\/jc.2010-1996","article-title":"Approach to the thyroid cancer patient with bone metastases.","volume":"96","author":"Wexler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20260708","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/MD.0000000000001063","article-title":"Long-term follow-up of the therapeutic outcomes for papillary thyroid carcinoma with distant metastasis.","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"R27-20260708","doi-asserted-by":"crossref","first-page":"R307","DOI":"10.1530\/ERC-13-0187","article-title":"Metastatic mechanisms in follicular cell-derived thyroid cancer.","volume":"20","author":"Phay","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"R28-20260708","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/jjco\/hyu099","article-title":"Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC): a retrospective study of 40 cases.","volume":"44","author":"Nakayama","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"R29-20260708","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1089\/thy.2009.1611","article-title":"The benefits and risks of i-131 therapy in patients with well-differentiated thyroid cancer.","volume":"19","author":"Van Nostrand","year":"2009","journal-title":"Thyroid"},{"key":"R30-20260708","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/thy.2006.16.1229","article-title":"Outcomes of patients with differentiated thyroid carcinoma following initial therapy.","volume":"16","author":"Jonklaas","year":"2006","journal-title":"Thyroid"},{"key":"R31-20260708","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1210\/jc.2014-4332","article-title":"Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.","volume":"100","author":"Ruel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20260708","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12149-014-0929-3","article-title":"Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed (131)I scan in differentiated thyroid cancer: a preliminary report.","volume":"29","author":"Lee","year":"2015","journal-title":"Ann Nucl Med"},{"key":"R33-20260708","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4158\/EP12077.OR","article-title":"Therapeutic implications of diffuse hepatic uptake following I-131 therapy for differentiated thyroid cancer.","volume":"19","author":"Ferris","year":"2013","journal-title":"Endocr Pract"},{"key":"R34-20260708","doi-asserted-by":"crossref","first-page":"e1191","DOI":"10.1097\/MD.0000000000001191","article-title":"A quantitative evaluation of hepatic uptake on I-131 whole-body scintigraphy for postablative therapy of thyroid carcinoma.","volume":"94","author":"Nakayama","year":"2015","journal-title":"Medicine (Baltim)"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:01:12Z","timestamp":1783490472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002159","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"2026-01-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}